Clinical Trials Logo

Pruritis clinical trials

View clinical trials related to Pruritis.

Filter by:
  • None
  • Page 1

NCT ID: NCT06226610 Not yet recruiting - Pruritis Clinical Trials

Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic

Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

The goal of this study is to test the efficacy of Dupixent in improving post-burn itching symptoms versus the current standard of care.

NCT ID: NCT05936567 Recruiting - Clinical trials for Chronic Spontaneous Urticaria

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

Start date: July 31, 2023
Phase: Phase 2
Study type: Interventional

This study is being conducted to evaluate the efficacy and safety of povorcitinib in adults with CSU that is inadequately controlled using SOC treatments.

NCT ID: NCT04518618 Completed - Pruritis Clinical Trials

Effect of Intrathecal Naloxone in the Incidence of Pruritis After C.S

Start date: September 11, 2020
Phase: N/A
Study type: Interventional

This randomized prospective double-blind trial will be conducted on 80 Full-term pregnant females aged 21- 30 years presented for elective cesarean section under spinal anesthesia where they will be randomly allocated into two equal groups:- - Group F (40 Patients): Patients in this group will receive spinal anesthesia with 10 mg hyperbaric bupivacaine (2 ml) plus 25 ug of fentanyl (0.5 ml). - Group FN (40 patients): Patients in this group will receive spinal anesthesia with 10 mg hyperbaric bupivacaine (2 ml) plus 25 ug of fentanyl (0.5 ml) plus 20 ug naloxone. The study aim is to evaluate the effect of adding an ultra-low dose of naloxone (20 ug) to hyperbaric bupivacaine (10 mg0 and fentanyl (25 ug) in spinal anesthesia for C.S. Primary outcome: The incidence of pruritis Secondary outcome: The onset, the duration, the site, and the severity of pruritis.

NCT ID: NCT03816891 Completed - Prurigo Nodularis Clinical Trials

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

Start date: March 11, 2019
Phase: Phase 2
Study type: Interventional

Study of the efficacy, safety, tolerability, pharmacokinetics (PK), and immunogenicity of Vixarelimab (KPL-716) in subjects with prurigo nodularis.

NCT ID: NCT02909569 Withdrawn - Pruritis Clinical Trials

Relieving Chronic Itch: Oral Medication

CIPS
Start date: August 2018
Phase: Phase 2
Study type: Interventional

This study evaluates the effect of twice daily dose of INCB39110 in the treatment of itch in adults.

NCT ID: NCT01114672 Completed - Pruritis Clinical Trials

A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients

CRN11
Start date: July 2010
Phase: Phase 4
Study type: Interventional

Pruritis (itching) is common in many people with chronic renal failure on hemodialysis. There may be many different reasons for the pruritis. Efforts to treat the problem have not been very effective. Vitamin D levels have been found to be low in many hemodialysis patients. Since vitamin D plays an important role in the skin and is effective in treatment of certain skin conditions that involve pruritis, it may have a role in treatment of pruritis in hemodialysis patients. The objective of the investigators study is to determine the effect of supplementation with oral vitamin D2 (ergocalciferol) on pruritis in hemodialysis patients.

NCT ID: NCT00693654 Completed - Pruritis Clinical Trials

Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients

Start date: November 2006
Phase: Phase 4
Study type: Interventional

The purpose of this research study is to evaluate the efficacy of SARNA Sensitive Lotion in the treatment of uremic pruritus in adult hemodialysis patients in a double-blind Controlled comparative trial.

NCT ID: NCT00323154 Completed - Pruritis Clinical Trials

Nalbuphine for the Treatment of Opioid Induced Pruritus in Children

Start date: March 2004
Phase: Phase 3
Study type: Interventional

Itching is a frequent and disturbing side effect of the use of pain medication such as morphine. In the post-operative period, it can be more distressing to pediatric patients than their pain. The current first line treatment, an antihistamine (Benadryl), has a low efficacy. This treatment causes sleepiness and may be dangerous when used in combination with other drugs. Nalbuphine has analgesic properties similar to morphine as well as the ability to reverse some morphine-induced side effects, such as respiratory depression and itching. Nalbuphine has been used effectively for patients undergoing Caesarean sections. However, the effectiveness of nalbuphine in the pediatric population has not been investigated. We want to determine the efficacy of nalbuphine in the treatment of itching after morphine for postoperative pain relief. We will use a novel method to measure the effect of the treatment using an intensity scale before and after the drug, to determine the intensity difference.